Ampac Announces Low Extractable Barrier Lamination That Lowers Trace Contaminants
Ampac, a division of ProAmpac, announces a new low extractable barrier lamination, PRO FlexiPURE, which enhances the existing family of successful barrier drug and medical device overwrap laminations for the pharmaceutical and medical device markets.
As analytical equipment has improved, detection limits of trace contaminants have lowered. In filing new drug applications using packaging film, these detectable trace compounds must be included in the drug submission process, identified, risks analyzed, and monitored, all of which costs pharmaceutical companies time and money. The fewer of these components that are realized in the film structure, the less time and money needed to be spent on this portion of a new drug submission.